Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Monotherapy vs Combination in Low-Risk HER2+ Early Breast Cancer
NCT05388500Phase 3Not yet recruiting
- Sponsor
- Institut de cancérologie Strasbourg Europe
- Start
- Dec 2022
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of trastuzumab in HER2-positive breast cancer, sponsored by Institut de cancérologie Strasbourg Europe. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05388500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388500.